Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer lived without their disease progressing, according to interim data from a ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN ANTONIO -- ...
Merck MRK along with partner Eisai announced data from the phase III LEAP-015 study, which evaluated blockbuster PD-1 inhibitor, Keytruda (pembrolizumab) and Eisai’s TKI inhibitor, Lenvima (lenvatinib ...
Venetoclax improved PFS but not OS in relapsed/refractory multiple myeloma, with significant benefits in t(11;14) and/or BCL2high subgroups. The overall response rate was higher with venetoclax, and ...
The ORR with the combination was 19.0%, which surpassed the historical benchmark of 14.6% (P=0.0787), but failed to beat an ORR of ≥21% (one-sample z-test P≤0.0245) that was required to demonstrate ...
A twice-daily combination of tramadol and acetaminophen in acute low back pain missed its primary endpoint in a Phase III trial, sending shares of Labopharm Inc. sliding 10 percent, though the Laval, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback